Table 5.
Univariate and multivariate Cox proportional hazards regression model for disease free survival (DFS) and overall survival (OS).
| Parameters | Level | DFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||
| Hazard ratio (95%CI) | P | Hazard ratio (95%CI) | P | Hazard ratio (95%CI) | P | Hazard ratio (95%CI) | P | |||
| PD-L1 | Low expression | 1 (Reference) | 0.027 | 1 (Reference) | 0.011 | 1 (Reference) | 0.042 | 1 (Reference) | 0.001 | |
| High expression | 0.648(0.442-0.952) | 0.605(0.411-0.891) | 0.573(0.335-0.979) | 0.528(0.359-0.777) | ||||||
| Age | <46 | 1 (Reference) | 0.064 | 1 (Reference) | 0.628 | |||||
| ≥46 | 1.966(0.961-4.019) | 1.194(0.582-2.450) | ||||||||
| BMI | <23.63 | 1 (Reference) | 0.130 | 1 (Reference) | 0.023 | |||||
| ≥23.63 | 1.595(0.871-2.918) | 2.107(1.106-4.015) | ||||||||
| Family history | No | 1 (Reference) | 0.387 | 1 (Reference) | 0.023 | |||||
| Yes | 1.401(0.653-3.008) | 2.445(1.133-5.279) | ||||||||
| Menopause | No | 1 (Reference) | 0.082 | 1 (Reference) | 0.919 | |||||
| Yes | 0.463(0.194-1.103) | 0.958(0.420-2.183) | ||||||||
| Tumor site | Right | 1 (Reference) | 0.007 | 1 (Reference) | 0.008 | |||||
| Left | 2.065(1.219-3.497) | 2.175(1.225-3.862) | ||||||||
| Clinical T stage | T1 | 1 (Reference) | 0.231 | 1 (Reference) | 0.132 | |||||
| T2+T3+T4 | 1.662(0.724-3.814) | 1.990(0.813-4.870) | ||||||||
| Clinical N stage | N0 | 1 (Reference) | 0.346 | 1 (Reference) | 0.661 | |||||
| N1+N2+N3 | 0.508(0.124-2.076) | 0.748(0.204-2.739) | ||||||||
| Clinical TNM stage | I | 1 (Reference) | 0.825 | 1 (Reference) | 0.997 | |||||
| II+III | 1.354(0.092-19.834) | 1.005(0.064-15.808) | ||||||||
| Neoadjuvant chemotherapy regimen | AC/ACF/CT/ACT/AT | 1 (Reference) | 0.008 | 1 (Reference) | 0.018 | |||||
| TP/Others | 0.408(0.209-0.795) | 0.425(0.209-0.862) | ||||||||
| Duration of neoadjuvant therapy | <6 | 1 (Reference) | 0.003 | 1 (Reference) | 0.002 | 1 (Reference) | 0.007 | 1 (Reference) | 0.002 | |
| ≥6 | 2.904(1.436-5.873) | 1.998(1.285-3.105) | 2.699(1.312-5.550) | 1.973(1.291-3.016) | ||||||
| Response | PR | 1 (Reference) | 0.306 | 1 (Reference) | 0.685 | |||||
| SD+PD | 0.747(0.428-1.305) | 0.898(0.533-1.512) | ||||||||
| Type of surgery | Mastectomy | 1 (Reference) | 0.320 | 1 (Reference) | 0.177 | |||||
| Breast-conserving surgery | 0.660(0.291-1.497) | 0.596(0.281-1.263) | ||||||||
| Pathological Tumor size | ≤2cm | 1 (Reference) | 0.542 | 1 (Reference) | 0.807 | |||||
| >2cm | 1.530(0.390-6.001) | 0.826(0.178-3.842) | ||||||||
| MPG | 1+2 | 1 (Reference) | 0.558 | 1 (Reference) | 0.005 | 1 (Reference) | 0.010 | |||
| 3+4+5 | 1.209(0.641-2.280) | 2.431(1.311-4.510) | 1.984(1.174-3.353) | |||||||
| Histologic type | Noninvasive carcinoma | 1 (Reference) | 0.720 | 1 (Reference) | 0.621 | |||||
| Invasive nonspecific carcinoma | 1.490(0.168-13.226) | 1.697(0.209-13.807) | ||||||||
| Histologic grade | I | 1 (Reference) | 0.492 | 1 (Reference) | 0.251 | |||||
| II+III | 1.829(0.327-10.234) | 0.354(0.060-2.090) | ||||||||
| Pathological T stage | T1 | 1 (Reference) | 0.723 | 1 (Reference) | 0.461 | |||||
| T2+T3+T4 | 1.313(0.292-5.906) | 1.843(0.363-9.347) | ||||||||
| Pathological N stage | N0 | 1 (Reference) | 0.373 | 1 (Reference) | 0.748 | |||||
| N1+N2+N3 | 2.076(0.417-10.336) | 1.244(0.329-4.705) | ||||||||
| Pathological TNM stage | I | 1 (Reference) | 0.091 | 1 (Reference) | 0.055 | |||||
| II+III | 0.235(0.044-1.258) | 0.207(0.041-1.034) | ||||||||
| TLN | <24 | 1 (Reference) | 0.686 | 1 (Reference) | 0.146 | |||||
| ≥24 | 1.119(0.649-1.930) | 0.647(0.360-1.164) | ||||||||
| PLN | <2 | 1 (Reference) | 0.479 | 1 (Reference) | 0.030 | 1 (Reference) | 0.000 | |||
| ≥2 | 1.415(0.541-3.700) | 2.769(1.105-6.937) | 2.156(1.402-3.317) | |||||||
| Postoperative pathology | ||||||||||
| Molecular subtype | Luminal A/B HER2+/B HER2- | 1 (Reference) | 0.543 | 1 (Reference) | 0.304 | |||||
| HER2 enriched/Triple negative | 1.539(0.384-6.172) | 2.322(0.466-11.569) | ||||||||
| ER | 0-25% | 1 (Reference) | 0.023 | 1 (Reference) | 0.001 | |||||
| 26-100% | 6.765(1.296-35.322) | 25.813(3.734-178.431) | ||||||||
| PR | 0-25% | 1 (Reference) | 0.738 | 1 (Reference) | 0.216 | |||||
| 26-100% | 0.889(0.447-1.770) | 1.609(0.757-3.419) | ||||||||
| HER2 | Negative | 1 (Reference) | 0.485 | 1 (Reference) | 0.514 | |||||
| Positive | 0.698(0.254-1.919) | 0.718(0.265-1.945) | ||||||||
| Ki-67 | 0-25% | 1 (Reference) | 0.020 | 1 (Reference) | 0.015 | |||||
| 26-100% | 2.862(1.184-6.921) | 2.786(1.219-6.368) | ||||||||
| AR | 0-25% | 1 (Reference) | 0.619 | 1 (Reference) | 0.072 | |||||
| 26-100% | 1.261(0.505-3.150) | 0.402(0.149-1.085) | ||||||||
| CK5/6 | Negative | 1 (Reference) | 0.292 | 1 (Reference) | 0.006 | |||||
| Positive | 0.630(0.266-1.489) | 0.300(0.128-0.704) | ||||||||
| E-cad | Negative | 1 (Reference) | 0.022 | 1 (Reference) | 0.007 | 1 (Reference) | 0.000 | 1 (Reference) | 0.014 | |
| Positive | 2.415(1.133-5.146) | 1.934(1.196-3.126) | 5.356(2.250-12.749) | 1.984(1.147-3.431) | ||||||
| EGFR | Negative | 1 (Reference) | 0.303 | 1 (Reference) | 0.009 | |||||
| Positive | 1.595(0.656-3.877) | 3.560(1.368-9.264) | ||||||||
| P53 | 0-25% | 1 (Reference) | 0.291 | 1 (Reference) | 0.014 | |||||
| 26-100% | 1.443(0.730-2.852) | 2.270(1.183-4.357) | ||||||||
| TOP2A | 0-25% | 1 (Reference) | 0.381 | 1 (Reference) | 0.720 | |||||
| 26-100% | 0.672(0.276-1.635) | 0.870(0.405-1.867) | ||||||||
| Lymph vessel invasion | Negative | 1 (Reference) | 0.767 | 1 (Reference) | 0.757 | |||||
| Positive | 0.903(0.460-1.772) | 1.119(0.549-2.284) | ||||||||
| Neural invasion | Negative | 1 (Reference) | 0.101 | 1 (Reference) | 0.405 | |||||
| Positive | 1.997(0.873-4.565) | 1.392(0.640-3.029) | ||||||||
| Postoperative chemotherapy | Negative | 1 (Reference) | 0.291 | 1 (Reference) | 0.004 | |||||
| Positive | 1.511(0.703-3.247) | 3.244(1.445-7.280) | ||||||||
| Postoperative radiotherapy | Negative | 1 (Reference) | 0.573 | 1 (Reference) | 0.678 | |||||
| Positive | 0.801(0.370-1.735) | 1.178(0.543-2.555) | ||||||||
| Postoperative endocrine therapy | Negative | 1 (Reference) | 0.012 | 1 (Reference) | 0.000 | |||||
| Positive | 0.408(0.202-0.823) | 0.192(0.095-0.387) | ||||||||
| Targeted therapy | Negative | 1 (Reference) | 0.003 | 1 (Reference) | 0.000 | 1 (Reference) | 0.000 | 1 (Reference) | 0.000 | |
| Positive | 3.898(1.602-9.486) | 3.037(1.976-4.670) | 6.576(2.565-16.860) | 3.322(2.192-5.036) | ||||||
MPG, Miller-Payne grade; TLN, total lymph node; PLN, positive lymph node; ER, estrogen receptor, PR, progesterone receptor; HER2, Human Epidermal Growth Factor Receptor 2; AR, androgen receptor; E-cad, E-Cadherin; EGFR, epidermal growth factor receptor; TOP2A, Topoisomerase II-α